REG - Oxford Nanopore Tech - Oxford Nanopore and UK Biobank collaboration

Oxford Nanopore TechnologiesAnnouncement

27/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241127:nRSa8344Na&default-theme=true

RNS Number : 8344N  Oxford Nanopore Technologies plc  27 November 2024

 

27 November 2024

Oxford Nanopore Technologies plc

Oxford Nanopore and UK Biobank to create world's largest epigenetic dataset
targeting the causes of cancer, dementia, complex disease

-     The project will utilise Oxford Nanopore's technology to map the
epigenome using 50,000 UK Biobank participant samples, to unlock crucial
insights into disease mechanisms

 

-     The initiative builds upon a new strategic partnership between UK
Biobank, Genomics England and NHS England to drive biomedical research forward
and improve patient outcomes in the UK and beyond

 

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or "the
Group"), the company delivering a new generation of nanopore-based molecular
sensing technology, today announces a new collaboration with UK Biobank to
create the world's first comprehensive, large-scale epigenetic dataset.

Oxford Nanopore technology will be utilised to analyse the epigenome using
50,000 participant samples to unlock crucial insights into disease mechanisms.
This research project is expected to run for up to 24 months, deploying 15-30x
coverage of epigenetic sequencing to characterise potential causes of diseases
including cancer, neurological diseases and other common complex diseases.

Epigenetics is the study of how external factors and lifestyle choices can
modify an individual's DNA. Epigenetic changes play a critical role in how
genes are expressed and influence risk in diseases such as cancer and
neurodegeneration. Oxford Nanopore's technology provides a comprehensive view
of up to 98% of the epigenetic methylation markers, enabling richer insights
than traditional sequencing technologies, without the need for additional
complex chemical processes, such as bilsufite conversion.

This epigenetics programme follows the previously announced
(https://nanoporetech.com/news/oxford-nanopore-announces-landmark-uk-government-partnership-to-advance-genomics-driven-healthcare-innovation-in-the-uk)
strategic partnership with the UK Government, including the creation of the
first real-time, pathogen-agnostic biosurveillance system across as many as 30
hospitals in NHS England-creating an early warning framework to detect and
respond to emerging pandemics and biological threats.

These partnerships will not result in a change to the Group's already stated
2024 and medium-term financial guidance, with the incremental revenues
supporting the Group's previously stated revenue target of more than 30%
constant currency growth on a compound annual growth rate between FY24 and
FY27.

Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, commented:

"This project represents a significant leap forward in epigenetics research,
an increasingly important area of study related to causes of disease, disease
progression and response to treatment. Working with UK Biobank to create the
world's largest epigenetic dataset aligns with our commitment to drive
discovery in healthcare and genomics. By capturing comprehensive methylation
data, we aim to open new doors for understanding disease, especially cancer
and dementia, and ultimately enable more personalised, effective treatments
for patients."

 

-ENDS-

 

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com (mailto:ir@nanoporetech.com)

Media:              media@nanoporetech.com
(mailto:media@nanoporetech.com)

 

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com
(mailto:OxfordNanoporeTechnologies@teneo.com)

 

About Oxford Nanopore Technologies plc:

 

Oxford Nanopore Technologies' goal is to bring the widest benefits to society
through enabling the analysis of anything, by anyone, anywhere. The Group has
developed a new generation of nanopore-based sensing technology that is
currently used for real-time, high-performance, accessible, and scalable
analysis of DNA and RNA. The technology is used in more than 125 countries, to
understand the biology of humans, plants, animals, bacteria, viruses and
environments as well as to understand diseases such as cancer.  Oxford
Nanopore's technology also has the potential to provide broad, high impact,
rapid insights in a number of areas including healthcare, food and
agriculture.

For more information please visit: www.nanoporetech.com
(https://www.nanoporetech.com)

 

 

Forward-looking statements

This announcement contains certain forward-looking statements. For example,
statements regarding expected revenue growth and profit margins are
forward-looking statements. Phrases such as "aim", "plan", "expect", "intend",
"anticipate", "believe", "estimate", "target", and similar expressions of a
future or forward-looking nature should also be considered forward-looking
statements. Forward-looking statements address our expected future business
and financial performance and financial condition, and by definition address
matters that are, to different degrees, uncertain. Our results could be
affected by macroeconomic conditions, delays or challenges in manufacturing or
delivering of products to our customers, suspensions of large projects and/or
acceleration of large products or accelerated adoption of pathogen
surveillance or applied uses of our products. These or other uncertainties may
cause our actual future results to be materially different than those
expressed in our forward-looking statements.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQDLBLZFLEFBZ